EN DE
Watch Rapport Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rapport Therapeutics, Inc. (RAPP) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Rapport Therapeutics, Inc. stock $7.94, price $24.44, that is 67.5% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

RT Rapport Therapeutics, Inc. logo Thin data Nov 7, 2026

Rapport Therapeutics, Inc.

RAPP · US
Very expensive, weak quality

Our calculation puts a fair price 68% below what the stock costs today.

Insiders bought $22.0M (6M) · sold $8.1M
Fair value $7.94 · Strongly overvalued
Quality 35/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 8/100 · thin data
Negative coverage
Thin data
Watch Rapport Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$52.50 $7.15 Fair Value $7.94 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

29‑month range $7.15 – $52.50 · fair‑value band $5.24 – $9.93 · the $24.44 price screens above the $7.94 fair value. As of Nov 7, 2026.

Follow Rapport Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Rapport Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.

Show moreShow less

The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders.

The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Stock analysis

Rapport Therapeutics, Inc. (RAPP) currently trades at $24.44, while our model-based Fair Value estimate is $7.94, 68% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: $5.24 (bear) to $9.93 (bull), the price of $24.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Rapport Therapeutics, Inc. Common Stock reported revenue of $0 in FY2025 versus $0 in FY2023. Reported net income was −$111M in FY2025.

Key figures

Market cap $1.4B Small · P/S ratio 72.4 · EPS (TTM) $−3.17 · Return on equity −33.3% · Return on assets (EBIT) −26.7% (4-year average) · Operating margin −838% · Revenue (TTM) $20.0M · Free cash flow −$88.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −68%, RAPP screens richer than that median.

Fair Value models

Bear $5.24 Fair Value $7.94 Bull $9.93
Price $24.44 · Downside -67.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $5.24 $7.94 $9.93 52
All 1 models by family
Asset-Based
NCAV (Graham) $5.24 $7.94 $9.93 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 15
How calm the share price moves, does not count
Price momentum 15
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 16
Distance to the 52-week high, does not count
New shares 35
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors bought shares worth $22.0M, most recently on Oct 28, 2026. Over the same period, 3 people sold shares worth $8.1M. Buying cluster

  • BuyJames HealyDirector969,480 shares at $21.00$20.4MOct 28, 2026
  • BuyRamiro SanchezDirector3,600 shares at $27.35$98,478Oct 23, 2026
  • BuyJohn MaraganoreDirector9,411 shares at $26.45$248,891Oct 22, 2026
  • BuySteven M PaulDirector35,714 shares at $27.28$974,278Oct 22, 2026
  • BuyWendy B. YoungDirector3,789 shares at $26.39$99,992Oct 22, 2026
  • BuyPaul M SilvaDirector3,680 shares at $27.08$99,636Oct 22, 2026
  • SaleAbraham CeesayChief Executive Officer, Director13× since Nov 17, 2025: 149,876 shares, avg. $39.98$6.0MOct 21, 202610b5-1 plan
  • BuyTroy A. IgnelziChief Financial Officer5,500 shares at $26.10$143,550Oct 21, 2026
  • SaleCheryl GaultChief Operating Officer5× since Nov 26, 2025: 37,014 shares, avg. $33.45$1.2MSep 30, 2026
  • SaleKrishnaswamy YeleswaramChief Development Officer7× since Dec 31, 2025: 103,969 shares, avg. $42.87$4.5MAug 25, 2026

Plus 3 more entries from the last 12 months.

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

RAPP screens overvalued: fair value 68% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (60 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.
Note from the team Nov 1, 2026
AI conclusion: Positive Phase 2 results enabling major funding form the main strength while persistent cash burn with zero revenue remains the core weakness.
Main risk: Future conversion of notes risks increasing share count and complicating capital access for ongoing late-stage trials.
Rapport raised roughly 350 million dollars through discounted common stock and convertible notes just after positive Phase 2 results for RAP-219 in bipolar mania. The move extends cash runway well into 2029 to support multiple late-stage trials but increases share count and introduces future conversion risk. Our models currently see the stock as overvalued. Will the added resources speed up proof of concept across its precision neurology programs faster than dilution weighs on returns?
Join the discussion →

Compare Rapport Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −67.5% · Below median
Profitability
Return on assets −21.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.99× · Pricier than median
P/S (12 months) 72.44× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs RAPP
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs RAPP
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs RAPP
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs RAPP
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs RAPP
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs RAPP
argenx SE ARGX $927.21 $908.40 −2% vs RAPP
CSL Limited CSL A$200.77 A$183.04 −9% vs RAPP
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs RAPP
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs RAPP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rapport Therapeutics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rapport Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/RAPP

Frequently asked questions

Is Rapport Therapeutics, Inc. (RAPP) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $7.94 versus a price of $24.44, about 68% lower (overvalued).
What is the fair value of RAPP?
Our model-based fair value for Rapport Therapeutics, Inc. is $7.94 (as of Nov 7, 2026), built from audited fundamentals. The current price: $24.44.
What is the quality score of RAPP?
Rapport Therapeutics, Inc. has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rapport Therapeutics, Inc. (RAPP)?
Our model-based price target is the fair value of $7.94 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $5.24, optimistic scenario $9.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Rapport Therapeutics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $7.94, about 68% lower versus a price of $24.44 (overvalued). Cautious scenario $5.24, optimistic scenario $9.93. The calculation is refreshed regularly with new filings.
What is the revenue of Rapport Therapeutics, Inc. (RAPP)?
Rapport Therapeutics, Inc. reported trailing-twelve-month revenue of about $20.0M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Rapport Therapeutics, Inc. (RAPP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rapport Therapeutics, Inc. it is $7.94 per share (as of Nov 7, 2026), against a price of $24.44. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Rapport Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 7, 2026, RAPP trades above its calculated fair value: price $24.44, fair value $7.94, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RAPP?
No. The price is what the market pays today ($24.44); the fair value is what the company's own numbers justify ($7.94). For Rapport Therapeutics, Inc. the two are $16.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rapport Therapeutics, Inc. Common Stock worth?
The market values Rapport Therapeutics, Inc. at about $1.4B (market capitalisation, as of Nov 7, 2026). Per share that is $24.44; our models calculate a fair value of $7.94 per share.
What do the bullish and bearish scenarios say about RAPP?
Our models span a range for Rapport Therapeutics, Inc.: cautious scenario $5.24, base $7.94, optimistic $9.93 per share (as of Nov 7, 2026, price $24.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rapport Therapeutics, Inc. (RAPP)?
Balance-sheet figures for Rapport Therapeutics, Inc. (as of Nov 7, 2026): return on equity −33.3%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is RAPP from its 52-week high?
Rapport Therapeutics, Inc. trades at $24.44, about 53% below its 52-week high of $52.50 and 9% above the low of $22.50 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $7.94 is for.
Which stocks are comparable to Rapport Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rapport Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 7, 2026: price $24.44, calculated fair value $7.94 (−68%), Quality Score 35/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RAPP calculated?
We run Rapport Therapeutics, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $7.94 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rapport Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rapport Therapeutics, Inc. (RAPP)?
The closing price on Nov 6, 2026 was $24.44. Our model-based fair value is $7.94, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rapport Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($9.93). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($5.24 to $9.93) leaves room in how you read the outcome.

Key figures of Rapport Therapeutics, Inc.

How large is the market capitalisation of Rapport Therapeutics, Inc. (RAPP)?
The market capitalisation of Rapport Therapeutics, Inc. is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rapport Therapeutics, Inc. (RAPP)?
The price-to-sales ratio of Rapport Therapeutics, Inc. is 72.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rapport Therapeutics, Inc. (RAPP)?
Earnings per share at Rapport Therapeutics, Inc. are $−3.17. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Rapport Therapeutics, Inc. (RAPP)?
The return on equity (ROE) of Rapport Therapeutics, Inc. is −33.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rapport Therapeutics, Inc. (RAPP)?
On an EBIT basis the return on assets of Rapport Therapeutics, Inc. is −26.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rapport Therapeutics, Inc. (RAPP)?
The operating margin of Rapport Therapeutics, Inc. is −838% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Rapport Therapeutics, Inc. (RAPP) generate?
The free cash flow of Rapport Therapeutics, Inc. is −$88.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rapport Therapeutics, Inc. (RAPP) hold?
Rapport Therapeutics, Inc. holds more cash than debt, $41.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Rapport Therapeutics, Inc. Common Stock in the live analysis

One click puts Rapport Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.